Menu
The life-changing experience of receiving a kidney transplant all starts with the referral for evaluation. When considering a patient for a kidney transplant, the evaluation team considers the patient’s physical health, mental health, and finances. In this session, the panelists will provide an overview of the transplant evaluation process, explain how this process can lead to inequities in who receives a transplant, and empower patients to take an active role in conversations with their health providers. This talk will be brought to life by a patient who has been through this process multiple times and can offer hope for patients considering this option.
Join Chef Linda Blaylock, as she guides us through how to make a tasty and kidney friendly Polenta & Egg Breakfast Cup.
The “silent” nature of stage 3 chronic kidney disease (CKD) often leads to a delayed diagnosis, and subsequently delayed treatment. Because diabetes is the leading cause of CKD, individuals with diabetes should have their primary care provider regularly test them for kidney disease to ensure a timely diagnosis and treatment intervention to slow progression. Panelists will discuss diabetic kidney disease (DKD), ways to manage DKD through testing, medicine, and working with a dietitian. In addition, one of the panelists brings the perspective of living with DKD and will share his experience and changes he made to his lifestyle that made a difference.
This session is made possible thanks to generous support from Boehringer lngelheim/Lilly.
Sponsor Name
AKF fights for the futures of kidney patients and their families. Listen to how these kids are fighting for a better tomorrow.
With all the changes in kidney disease testing over the years, it can be unclear which tests provide the most accurate diagnosis. In this session, the panelists will be providing an overview of the landscape of kidney disease testing from the past, present, and future. The panelists will review the most common tests used to date (UACR and eGFR) and discuss the issues associated with each. In addition, the panelists will highlight recent changes to the eGFR equation and will discuss the future of kidney disease testing (cystatin-C, biomarkers, etc.). The goal of this session will be to bring awareness to the changes in kidney disease testing to empower the public to advocate for the test that is best for them.
Sponsor Name
The Apolipoprotein L 1 (APOL 1) gene is part of the APOL gene family, which plays a role in innate immunity, our body’s built-in system to fight threats. In some individuals, this gene has evolved to protect against a parasite that causes African human trypanosomiasis (African sleeping sickness); unfortunately, this protection against one disease has also been shown to cause significant kidney damage in some. Today, people of African ancestry all around the world may carry these APOL 1 variations, including people who identify as African American, AfroCaribbean and Latino/Latina.
Having two variations in the APOL 1 gene is associated with increased risk of kidney disease and even kidney failure, so it’s important to understand your genotype and whether you are at increased risk of kidney disease. For those who have APOL 1-mediated kidney disease (AMKD), early detection can help patients and their physicians choose appropriate treatment, identify potential risk to other family members, and prepare for more rapid disease progression.
In this session, panelists will provide an overview of the APOL 1 gene and how an individual’s ancestry may play a role in how the gene affects certain populations, especially those of African and Afro-Latin ancestry. Panelists will discuss genetic testing options (how to find out if you have this genetic variant) and how a patient’s life may be affected by a positive APOL 1 genetic test result.
This session is made possible thanks to the generous support from Vertex Pharmaceuticals Inc.
Sponsor Name
Join Licensed Clinical Social Worker, Elle Lee, as she discusses common mental health conditions associated with CKD.
With all the changes in kidney disease testing over the years, it can be unclear which tests provide the most accurate diagnosis. In this session, the panelists will be providing an overview of the landscape of kidney disease testing from the past, present, and future. The panelists will review the most common tests used to date (UACR and eGFR) and discuss the issues associated with each. In addition, the panelists will highlight recent changes to the eGFR equation and will discuss the future of kidney disease testing (cystatin-C, biomarkers, etc.). The goal of this session will be to bring awareness to the changes in kidney disease testing to empower the public to advocate for the test that is best for them.
Sponsor Name
AKF works on behalf of the 37 million Americans living with and at risk for kidney disease. From prevention to life after a transplant, AKF supports people wherever they are in their fight against kidney disease.
Contact us at [email protected] if you have questions or need help registering.
